Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
2 patients with metastatic breast cancer that were ER+ on IHC but lacked tracer avidity on 18 F-FES PET/CT.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
We hypothesize that despite ER detection on IHC, these receptors were nonfunctional, lacking the ability to bind estrogen. Since functional ER is a prerequisite for response to ET, these patients are not likely to respond to ET.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
Immunohistochemistry (IHC) is routinely used to determine the estrogen receptor (ER) expression status of breast cancer.
APA
Lawal IO, Li X, et al. (2026). Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry.. Clinical nuclear medicine, 51(4), e244-e246. https://doi.org/10.1097/RLU.0000000000006023
MLA
Lawal IO, et al.. "Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry.." Clinical nuclear medicine, vol. 51, no. 4, 2026, pp. e244-e246.
PMID
40474373 ↗
Abstract 한글 요약
Immunohistochemistry (IHC) is routinely used to determine the estrogen receptor (ER) expression status of breast cancer. 18 F-fluoro-estradiol ( 18 F-FES) PET/CT is indicated for select breast cancer patients with ER+ breast cancer, and patients with tracer-avid disease typically enjoy favorable responses to endocrine therapy (ET). We present 2 patients with metastatic breast cancer that were ER+ on IHC but lacked tracer avidity on 18 F-FES PET/CT. We hypothesize that despite ER detection on IHC, these receptors were nonfunctional, lacking the ability to bind estrogen. Since functional ER is a prerequisite for response to ET, these patients are not likely to respond to ET.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.